

formoterol with glycopyrrolate oral inhaler (BEVESPI)

Diagnosis Considered for Coverage:

- Chronic Obstructive Pulmonary Disease (COPD)

Coverage Criteria:

For diagnosis listed above:

- Inadequate response, intolerable side effect, or contraindication to Anoro Ellipta, **and**
- Dose does not exceed two puffs inhaled twice a day.

Coverage Duration: one year

Effective Date: 09/27/2023